211 related articles for article (PubMed ID: 35685506)
1. Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis.
Chen M; Liu J; Xiong Y; Xu G
Int J Clin Pract; 2022; 2022():4996239. PubMed ID: 35685506
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Chen M; Zhang X; Xiong Y; Xu G
Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis.
Zheng Q; Yang H; Liu W; Sun W; Zhao Q; Zhang X; Jin H; Sun L
BMJ Open; 2019 Sep; 9(9):e030919. PubMed ID: 31511292
[TBL] [Abstract][Full Text] [Related]
4. Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis.
Liu D; Yang Y; Kuang F; Qing S; Hu B; Yu X
Int Immunopharmacol; 2019 May; 70():354-361. PubMed ID: 30852290
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
Lin W; Li HY; Lin S; Zhou T
Drug Des Devel Ther; 2019; 13():2179-2186. PubMed ID: 31308629
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials.
Huang H; Liang Z; Zheng X; Qing Q; Du X; Tang Z; Wei M; Wang C; Zhong Q; Lin X
Ren Fail; 2021 Dec; 43(1):840-850. PubMed ID: 34016023
[TBL] [Abstract][Full Text] [Related]
8. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis.
Dai P; Xie W; Yu X; Sun J; Wang S; Kawuki J
Int Immunopharmacol; 2021 May; 94():107376. PubMed ID: 33582591
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
Peng L; Wei SY; Li LT; He YX; Li B
J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus combined with corticosteroids in patients with idiopathic membranous nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Tian Z; Li Y; Xie Y; Yang Y; Xu J
Int Urol Nephrol; 2022 Oct; 54(10):2555-2566. PubMed ID: 35277831
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis.
Liu J; Li X; Huang T; Xu G
Front Pharmacol; 2022; 13():917532. PubMed ID: 35959430
[No Abstract] [Full Text] [Related]
14. Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis.
You L; Ye P; Xiao G; Liang J; Kong Y
Turk J Med Sci; 2021 Dec; 51(6):2870-2880. PubMed ID: 34391323
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Jul; 100(28):e26628. PubMed ID: 34260552
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Agents in IgA Nephropathy: An Update Network Meta-Analysis.
Yang P; Wang Q; Xie C; Xu G; Wu Q
Kidney Blood Press Res; 2018; 43(6):1890-1897. PubMed ID: 30566932
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
[TBL] [Abstract][Full Text] [Related]
19. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Dec; 100(51):e28225. PubMed ID: 34941086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
